Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes
Open Access
- 28 March 2018
- journal article
- research article
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 38 (4) , 2311-2321
Abstract
Background/Aim: Recent interest has focused on the significance of tumor-infiltrating lymphocytes (TILs) on the efficacies and outcomes of the treatment in breast cancer (BC). Based on the recent international recommendation to standardize the evaluation method, the clinical validity and utility of TILs in patients who underwent neoadjuvant chemotherapy (NAC) were investigated in the present study. Patients and Methods: TILs were evaluated in 177 patients with BC treated with NAC and subsequent curative surgery. The correlation between TILs evaluated according to the standard method and prognosis, including the efficacy of NAC, was investigated retrospectively. Results: In the high-TIL group (n=96) compared to the low-TIL group (n=81), triple-negative breast cancer (TNBC) (p<0.001) and human epidermal growth factor receptor 2-enriched breast cancer (HER2BC) (p=0.040) were significantly more frequent, and the pathological complete response (pCR) rate was significantly higher (p=0.003). Among patients with TNBC and those with HER2BC, the pCR rate was significantly higher in the high-TIL group than in the low-TIL group (p=0.013 and p=0.014, respectively). Multivariable analysis also showed that high-TIL status was an independent factor predicting favorable prognosis (hazard ratio(HR)=0.24, p=0.023 and HR=0.13, p=0.036). Biopsy specimens from local recurrence after successful NAC frequently showed TILs decreased. Conclusion: TILs may be a biomarker for predicting treatment response to NAC in patients with TNBC and HER2BC. A decrease in TILs may also be associated with tumor recurrence.Keywords
This publication has 25 references indexed in Scilit:
- Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerBreast Cancer Research and Treatment, 2014
- PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patientsCancer Immunology, Immunotherapy, 2014
- Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?The Lancet Oncology, 2012
- The mechanisms of cancer immunoescape and development of overcoming strategiesInternational Journal of Hematology, 2011
- Immune parameters affecting the efficacy of chemotherapeutic regimensNature Reviews Clinical Oncology, 2011
- Mechanism of synergistic effect of chemotherapy and immunotherapy of cancerCancer Immunology, Immunotherapy, 2010
- A worldwide approach to the TNM staging system: Collaborative efforts of the AJCC and UICCJournal of Surgical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Preoperative chemotherapy for women with operable breast cancerCochrane Database of Systematic Reviews, 2007
- Cancer immunotherapy: moving beyond current vaccinesNature Medicine, 2004